Dr. Michael Hayden, Chief Executive Officer for Prilenia Therapeutics, and a Killam Professor at the University of British Columbia, joined the HD Insights Podcast to discuss the PROOF-HD clinical study. Prilenia is sponsor for the currently active PROOF-HD trial, a global study evaluating the efficacy and safety of pridopidine in patients with early stage of Huntington disease. Dr. Hayden spoke about this new study's unique endpoint for total functional capacity. You will also want to hear his inspiring personal journey that led him into Huntington disease research growing up in South Africa.
For more information on PROOF-HD, visit https://huntingtonstudygroup.org/proof-hd/.